利福昔明与乳果糖、拉克替醇治疗肝性脑病疗效和安全性的Meta分析

Safety and efficacy of rifaximin versus nonabsorbable disaccharides in treatment of hepatic encephalopathy:a meta analysis

目的评价利福昔明与乳果糖、拉克替醇非吸收性二糖治疗肝性脑病的疗效和安全性。方法计算机检索Pubmed,EMbase,Cochrane Library等数据库中关于利福昔明与非吸收二糖治疗肝性脑病的随机对照试验,同时按照制定的纳入与排除标准收集分析文献。结果利福昔明与非吸收二糖对比有同等的疗效（RR=1.06,95%CI=0.94～1.19,P〉0.05）。但与非吸收二糖相比,利福昔明安全性更高（RR=0.19,95%CI=0.10～0.34,P〈0.01）。结论利福昔明是治疗肝性脑病较非吸收二糖安全性更高的药物。

Objective To evaluate the efficacy and safety of rifaximin in comparison with nonabsorbable disaccharides.Methods The Pubmed,EMbase,Cochrane Library,EMBASE,CINAHL,and Science Citation Index（ISI Web of Science）were searched to collect all randomized controlled trials comparing rifaximin to nonabsorbable disaccharides for the treatment of hepatic encephalopathy,and the results by the inclusion and exclusion criteria were analyzed.Results The efficacy of rifaximin was equivalent to nonabsorbable disaccharides according to the statistical data（RR =1.06,95%CI =0.94-1.19,P〉0.05）.The safety of rifaximin was better than nonabsorbable disaccharides（RR =0.19,95%CI =0.10-0.34,P〈0.01）.Conclusion The safety of rifaximin is better than nonabsorbable disaccharides for the treatment of hepatic encephalopathy.